<DOC>
	<DOCNO>NCT02795754</DOCNO>
	<brief_summary>GSK2838232 Human Immunodeficiency Virus ( HIV ) maturation inhibitor develop treatment HIV combination antiretroviral therapy ( ART ) . The primary objective study investigate safety , tolerability , pharmacokinetics ( PK ) single repeat dos GSK2838232 . This study double-blind , placebo-controlled , single repeat dose escalation study . This study conduct two Parts : single escalating dos ( Part 1A 1B ) , repeat escalate daily ( QD ) dose 11 day ( Part 2 ) GSK2838232 co-dosed RTV . During Part 1A , single dos GSK2838232 ( active pharmaceutical ingredient-powder bottle [ API PiB ] ) 50 milligram ( mg ) , 100mg 200mg administer RTV . Part 1B evaluate relative bioavailability single dos crystalline active pharmaceutical ingredient ( API ) Immediate Release Tablet ( IR ) tablets versus API PiB reference , administer RTV . In Part 2 , multiple dos GSK2838232 co-administered RTV 100mg QD 11 day sequential dose cohort . Maximum duration study participation approximately 10 week .</brief_summary>
	<brief_title>Single Repeated Dose Escalation Study GSK2838232</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Age : Between 18 55 year age inclusive , time signing informed consent . Healthy determine Investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study , may include Investigator consultation Medical Monitor , require , agree document find unlikely introduce additional risk factor interfere study procedure A creatinine clearance ( CLcr ) &gt; 80milliliter/minute ( mL/min ) determine CockcroftGault equation CLcr ( mL/min ) = ( 140 age ) * weight ( Wt ) / ( 72 * serum creatinine [ Scr ] ) ( time 0.85 female ) age year , Wt kilogram ( kg ) , Scr unit milligram / decilitre ( mg/dL ) ; . Body weight &gt; = 50.0 kg ( 110 pound [ lb . ] ) men &gt; = 45.0kg ( 99lbs ) woman body mass index ( BMI ) Male female nonreproductive potential : A female subject eligible participate pregnant [ confirm negative serum human chorionic gonadotrophin ( hCG ) test ] , lactating , nonreproductive potential define : Premenopausal females one following : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy Post menopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ( refer laboratory reference range confirmatory level ) ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication one week last dose study medication . Vasectomy documentation azoospermia , Male condom plus partner use one contraceptive option follow : Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral Contraceptive , either combined progestogen alone . Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch . These allow method contraception effective use consistently , correctly accordance product label . The Investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent describe Study protocol include compliance requirement restriction list consent form protocol . Alanine aminotransferase bilirubin &gt; 1.0* upper limit normal ( ULN ) . Current chronic history liver disease , know hepatic biliary abnormality . Subjects asthma history asthma . Medical history cardiac arrhythmia cardiac disease family personal history long QT syndrome Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor , medication interfere study procedure compromise subject safety History regular alcohol consumption within 6 month study define : For US site : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150mL ) wine 1.5 ounce ( 45mL ) 80 proof distil spirit . Regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . Screening baseline cardiac troponin I great 99 % cutoff ( &gt; .045 nanograms/mL Dimension Vista Cardiac troponin assay ) give assay . A positive prestudy drug/alcohol screen . A positive test HIV antibody . Where participation study would result donation blood blood product excess 500mL within 56 day . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Exclusion Criteria 48Hour Screening Holter : Any symptomatic arrhythmia ( except isolate extra systole ) . Sustained cardiac arrhythmia ( atrial fibrillation flutter , supraventricular tachycardia ( &gt; =10 consecutive beat ) , complete heart block ) . Nonsustained sustain ventricular tachycardia ( define &gt; = 3 consecutive ventricular ectopic beat ) . Any conduction abnormality ( include specific leave right incomplete complete bundle branch block , atrioventricular ( AV ) block [ 2nd degree high ] , Wolf Parkinson White ( WPW ) syndrome etc. ) . Sinus Pauses &gt; 3 second . 300 supraventricular ectopic beat 24 hour . 250 ventricular ectopic beat 24 hour . Any clinically significant abnormal echocardiogram finding . Abnormal echocardiogram finding discuss Medical Monitor prior enrolment . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Heart rate Males &lt; 45 &gt; 100 beat per minute ( bpm ) , females &lt; 50 &gt; 100bpm PR Interval &lt; 120 &gt; 220 millisecond ( msec ) QRS duration &lt; 70 &gt; 120msec QT interval correct ( Fridericia 's ) &gt; 450msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK2838232</keyword>
	<keyword>HIV</keyword>
	<keyword>repeat dose escalation</keyword>
	<keyword>immediate release tablet</keyword>
	<keyword>single dose escalation</keyword>
</DOC>